AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
AbCellera’s full-stack, AI-powered drug discovery platform, which integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science, empowers drug developers of all sizes to move quickly, reduce costs, and tackle the toughest problems in drug development.
Notable Press Mentions
2021 EY Entrepreneur Of The Year Builds Biotech Powerhouse
AbCellera Acquires Tetragenetics, Announces Multi-year Partnership with Moderna
AbCellera to Collaborate with Tachyon, EQRx on Therapeutic Antibodies for Cancer
Vancouver Headquarter Groundbreaking and Manufacturing
Gilead again Partners for Multitarget Deal
Novartis Inks 10-target antibody discovery deal with AbCellera